BaseLaunch

Onena Medicines is a biotechnology company focused on developing innovative biological therapies to meet the significant clinical needs of breast cancer and other serious orphan diseases. The company utilizes a proprietary antibody drug discovery platform that leverages artificial intelligence to create custom antibodies with high selectivity and specificity. This platform is designed to reprogram cancer cells and modulate the activities of a novel set of growth factors known as dual smad inhibiting protein dips, which are believed to contribute to cancer growth and metastasis. By doing so, Onena Medicines aims to provide physicians with access to new treatment options in areas where there is a lack of effective therapies.

Phialogics is a preclinical biotechnology company that specializes in developing advanced biologics aimed at modulating the immune response in cases of acute and chronic inflammation. The firm focuses on creating cell therapies for the treatment of autoimmune diseases by employing protein engineering techniques to design cell-type-specific immune checkpoint activators. These innovations enable the production of signaling agonists that effectively influence the activity of immune cells, thereby assisting healthcare professionals in preventing multi-organ failure associated with autoimmune conditions.

Salvina Therapeutics is a biotechnology firm focused on advancing treatments for inflammatory and autoimmune diseases. The company has identified a novel epitope specifically targeting tumor necrosis factor (TNF), leading to the creation of antibodies with a unique mode of action. By developing innovative therapies, Salvina Therapeutics aims to overcome existing efficacy barriers and provide medical companies with effective solutions for challenging health conditions.

FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on endometriosis. The company aims to accelerate the journey toward effective cures by addressing significant healthcare needs and introducing novel solutions that enhance women's health. FimmCyte is dedicated to empowering women to take control of their health and tackle unmet medical needs associated with these conditions.

Engimmune Therapeutics is a biotechnology company focused on developing innovative T cell receptor (TCR) therapies for cancer treatment, particularly targeting solid tumors. The company utilizes advanced technologies, including genome editing, high-throughput screening, deep sequencing, and machine learning, to create highly potent and specific immunotherapies. By addressing critical challenges in efficacy and safety, Engimmune aims to provide effective solutions for patients facing serious diseases with significant unmet medical needs. Through its comprehensive platform, the company is dedicated to advancing the next generation of TCR-based therapies, contributing to the evolving landscape of cancer treatment.

Aukera Therapeutics is a biotechnology company focused on developing innovative therapeutics for patients affected by diseases related to the mTOR protein, including cancer and neurodegenerative disorders. Originating as a spin-off from the Biozentrum of the University of Basel, Aukera Therapeutics has established a pharmaceutical drug discovery engine that creates selective inhibitors of the mTOR complex. This technology aims to target various branches of the mTOR pathway, facilitating the development of treatments that not only address cancer but also manage the overactivity of the mTORC1 complex, which is crucial for regulating cell growth. Through its research and development efforts, Aukera Therapeutics strives to provide effective therapeutic options for patients with these challenging conditions.

Stromal Therapeutics is a biotechnology company that originated as a spin-off from Kantonsspital St.Gallen. The company focuses on developing innovative immunotherapies targeting tissue cytokines and their inhibitors produced by stromal cells. By utilizing advanced single-cell sequencing of human tissues, Stromal Therapeutics aims to elucidate the interactions between stromal tissue cytokines and the immune system. The company is advancing a lead compound that has shown efficacy in preclinical models for inflammatory heart disease, a condition currently lacking specific therapeutic options. Through its research, Stromal Therapeutics strives to enable healthcare professionals to treat inflammatory diseases by manipulating the tissue stroma.

PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing innovative treatments for gastrointestinal diseases. Founded in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create microbiome therapies aimed at conditions such as Clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome's technology platform enables efficient development and production of defined, function-based therapies, facilitating a swift transition from identifying therapeutic mechanisms to clinical-ready products. The company aims to establish microbiota therapy as the new standard for treating intestinal diseases, providing alternatives to traditional fecal transplants for patients suffering from intestinal infections.

Polyneuron Pharmaceuticals AG is a biotechnology company based in Basel, Switzerland, founded in 2014. The company focuses on developing innovative therapeutics for antibody-mediated autoimmune disorders, particularly those affecting the peripheral nervous system. Its lead candidates include PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron employs a unique platform technology called Antibody-Catch, which utilizes biodegradable glycopolymers to selectively target and eliminate pathogenic autoantibodies while preserving the overall integrity of the immune system. This approach aims to provide safe and effective treatment options for patients suffering from these complex immune disorders.

A IAstein é uma startup brasileira de EdTech que desenvolve soluções baseadas em Inteligência Artificial generativa para a resolução automatizada e explicada de questões. Nosso sistema utiliza NLP, modelos LLM e algoritmos de machine learning para fornecer respostas claras, fundamentadas e com justificativas — tornando o processo de estudo mais inteligente, rápido e personalizado. Fundada em janeiro de 2024, em Salvador (BA), a IAstein já impactou centenas de usuários em fase beta e foi selecionada por programas de aceleração regional. Em março de 2025, recebemos um investimento pré-seed de R$ 500.000 de um grupo de investidores-anjo e uma aceleradora focada em IA e educação.